Key result
Dual antiplatelet therapy is effective for the early secondary prevention of non-cardioembolic ischemic stroke but requires careful assessment of bleeding risks with long-term use.
Why the study?
Does dual antiplatelet therapy reduce recurrent stroke compared to monotherapy in patients with ischemic stroke or TIA?
Does dual antiplatelet therapy reduce recurrent stroke compared to monotherapy in patients with ischemic stroke or TIA?
This review highlights that while DAPT is effective for early stroke prevention, its bleeding risks necessitate short-term use, strict blood pressure control, and the development of safer antiplatelet agents targeting platelet adhesion.
Supports short-term DAPT for early non-cardioembolic stroke prevention; leaves open optimal duration and safer agents.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Yoshinari Nagakane (2017) conducted a review in Ischemic stroke. Dual antiplatelet therapy (DAPT) vs. Antiplatelet monotherapy was evaluated. Dual antiplatelet therapy is effective for the early secondary prevention of non-cardioembolic ischemic stroke but requires careful assessment of bleeding risks with long-term use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: